Core Viewpoint - A class action lawsuit has been initiated against Novo Nordisk A/S, alleging that the company made false or misleading statements regarding its CagriSema obesity study, leading to significant investor losses during the specified class period from November 2, 2022, to December 19, 2024 [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities during the class period and have until March 25, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Novo Nordisk failed to disclose critical information about the reliability of its projected success for the Phase 3 CagriSema obesity study, "REDEFINE-1" [5]. Group 2: Study Results and Impact - On December 20, 2024, Novo Nordisk reported results from the REDEFINE-1 trial, indicating that only 57.3% of CagriSema patients remained on the highest dose after 68 weeks, compared to 82.5% for cagrilintide 2.4 mg and 70.2% for semaglutide 2.4 mg [3]. - Following the release of these results, Novo Nordisk's stock price experienced a nearly 18% drop [3]. Group 3: Allegations of Misrepresentation - The lawsuit alleges that the company's claims regarding CagriSema achieving at least 25% weight loss in the REDEFINE-1 study were unrealistic [5]. - It is suggested that the study's "flexible protocol" limited its ability to provide meaningful weight loss data, indicating potential tolerability issues or a rushed patient selection process [5].

Core Viewpoint - Roche's collaboration deal with Zealand Pharma for the obesity drug petrelintide increases competition in the obesity treatment market, negatively impacting Novo Nordisk's stock performance [1][5]. Company Summary - Roche has entered a licensing agreement to co-develop petrelintide, a long-acting amylin analog, which is currently in phase IIb studies targeting individuals who are obese or overweight without type II diabetes [2][4]. - The deal includes an upfront payment of $1.65 billion, with total deal value reaching approximately $5.3 billion, including milestone payments [4]. - Novo Nordisk's stock has seen a significant decline of 14.2% this week and 44.4% over the past year, attributed to increased competition and disappointing data from its own obesity candidate, CagriSema [6][7]. Industry Summary - The obesity treatment market is becoming increasingly competitive, with Roche's entry posing a threat to the dominance of Novo Nordisk and Eli Lilly, who currently lead with their GLP-1 drugs [3][5]. - Other companies, such as Amgen and Viking Therapeutics, are also advancing in the development of GLP-1-based candidates, indicating a broader competitive landscape [8]. - The recent licensing of GUB014295 by AbbVie for obesity treatment further intensifies competition in the next-generation amylin class [9].

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submiss ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=135472&from=4 CLASS PERIOD: November 2, 2022 to ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-fo ...

Novo Nordisk (NVO) has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 diabetes (T2D) and a mean baseline body weight of 102 kg. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68 compared with placebo.NVO’s CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. T ...

On Monday, Novo Nordisk A/S NVO announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.The trial included 1,206 randomized people with obesity or overweight, type 2 diabetes, and a mean baseline body weight of 102 kg.The REDEFINE 2 trial was based on a flexible protocol, allowing pa ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Shares of Novo Nordisk A/S ( NVO ) are down today after the company reported underwhelmin ...

Core Insights - Novo Nordisk's stock experienced a significant decline of 8.9% amid broader market losses, with the S&P 500 down 1.7% and the Nasdaq Composite down 2.8% [1] Group 1: Trial Results - The trial results for Novo Nordisk's next-generation weight-loss drug CagriSema showed a weight loss of 15.7% in obese or overweight adult patients with type 2 diabetes, falling short of the expected 25% [2] - The disappointing results for CagriSema come at a critical time, as the company had positioned it as a successor to its successful weight-loss drugs Wegovy and Ozempic, which have been significant revenue generators [3] Group 2: Market Position - Despite the setback with CagriSema, Novo Nordisk is expanding its market presence by launching an online pharmacy, NovoCare, allowing consumers to purchase Wegovy at a discounted price of $499 per month [4] - CagriSema, while not meeting high expectations, still demonstrated solid weight loss compared to placebo and is considered to have a safe and well-tolerated profile, suggesting that Novo Nordisk remains well-positioned in the lucrative weight-loss drug market [5]

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial.  Novo's results from its Redefine 2 late-stage trial of CagriSema showed that patients on the highest dose of the drug lost 15.7% of their weight. Patients who were placed on the placebo lost 3.1%, according to the data. The trial included 1,206 people with obesity or who were overweight and had type 2 diabetes. They had a mean baseline body weight of about 224 pounds. Shares of ...